Clinical Hematology Research Career Development Program (K12)

临床血液学研究职业发展计划（K12）

• 批准号: 7194508
• 负责人: ELLIS J NEUFELD
• 金额: $ 39.91万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-28 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7194508
• 关键词: blood transfusion; bone marrow disorder; career; clinical research; health science research potential; hematology; hemoglobinopathy; mentoring /mentor; thromboembolism; training

DESCRIPTION (provided by applicant): The Clinical Hematology Research Career Development Program is a Harvard-wide initiative to support training in clinical research for non-malignant hematology. The long-term objective of the program is to attract and retain talented young physician scientists to the field of blood diseases. Current trends in adult hematology/oncology careers are toward oncology. This K12 scholars' program is aimed at reversing that trend. This proposed program is a joint effort of six primary Harvard-affiliated institutes and hospitals with major training and research programs in non-malignant hematology (alphabetically, Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital (BWH), Center for Blood Research Institute (CBRI), Children's Hospital, Boston (CHB), Dana Farber Cancer Institute (DFCI), and Mass. General Hospital (MGH)). The administrative home of the program is at CHB. The principal investigator is a pediatric hematologist with a track record of clinical research mentoring and active involvement in NHLBI clinical research networks. The site directors from the member hospitals are distinguished hematologists with strong track records in hematology research. More than 40 potential mentors are available, covering all of the project disciplines. Scholars in the K12 program will receive formal didactic training in responsible conduct of research, in clinical areas of non-malignant hematology, and in methodology for patient-oriented research. Masters programs of Harvard Medical School available for the latter training are (i) a K30-funded Scholars in Clinical Sciences Program; (ii) Program in Clinical Effectiveness (a joint program with the Harvard School of Public Health), and (iii) Clinical Investigator Training Program offered jointly by BWH, BIDMC, HMS and MIT. The initiative includes the major clinical areas of: aplastic anemia/bone marrow failure syndromes; hemoglobinopathies including sickle cell disease and thalassemia; hemophilia and other hemostatic disorders; venous thromboembolism and thrombophilias; myelodysplastic syndromes and myeloproliferative disorders; transfusion medicine, including unique aspects of pediatric transfusion medicine. Together, the member institutions host more than 7,000 annual ambulatory hematology visits. Clinical research resources include three NHLBI clinical trials networks, four large GCRCs, sub-contract sites for the Boston Cooperative Sickle Cell Center, the Boston Hemophilia Center, and the resources of the DFCI/Harvard Cancer Center. An advisory committee composed of specialists in each key area, representing all six institutes/hospitals will oversee the project and serve as the admissions committee. Scholar Applicants will be drawn primarily from among the training programs at the member hospitals in Hematology/Oncology and Transfusion Medicine. Typically trainees will spend two years as scholars, pursuing an independent research project along with their didactic training. A colloquium series in non-malignant hematology will bring together scholars, their mentors, program faculty and other hematologists from around the Boston Hematology community. Formal annual evaluation of the program and of trainees' progress will be used for ongoing program improvements.

描述（由申请人提供）： 临床血液学研究职业发展计划是哈佛大学范围内的一项计划，旨在支持非恶性血液学临床研究培训。该计划的长期目标是吸引和留住有才华的年轻医师科学家进入血液疾病领域。目前成人血液学/肿瘤学职业的趋势是向肿瘤学发展。 K12 学者计划旨在扭转这一趋势。该拟议项目是哈佛附属六家主要机构和医院的共同努力，这些机构和医院在非恶性血液学方面拥有主要培训和研究项目（按字母顺序排列，贝斯以色列女执事医疗中心 (BIDMC)、布莱根妇女医院 (BWH)、血液中心研究所 (CBRI)、波士顿儿童医院 (CHB)、达纳法伯癌症研究所 (DFCI) 和麻省总医院 (MGH)。该计划的行政总部位于 CHB。主要研究者是一名儿科血液学家，拥有临床研究指导记录并积极参与 NHLBI 临床研究网络。成员医院的站点负责人都是杰出的血液学家，在血液学研究方面拥有良好的记录。超过 40 名潜在导师可供选择，涵盖所有项目学科。 K12 项目的学者将接受正式的教学培训，涉及负责任的研究行为、非恶性血液学临床领域以及以患者为导向的研究方法。哈佛医学院可供后者培训的硕士课程有：（i）K30资助的临床科学学者项目； (ii) 临床有效性计划（与哈佛大学公共卫生学院的联合计划），以及 (iii) BWH、BIDMC、HMS 和 MIT 联合提供的临床研究者培训计划。该倡议包括以下主要临床领域：再生障碍性贫血/骨髓衰竭综合征；血红蛋白病，包括镰状细胞病和地中海贫血；血友病及其他 止血障碍;静脉血栓栓塞和血栓形成倾向；骨髓增生异常综合征和 骨髓增生性疾病；输血医学，包括儿科输血医学的独特方面。成员机构每年共同接待 7,000 多次门诊血液学就诊。临床研究资源包括三个 NHLBI 临床试验网络、四个大型 GCRC、波士顿镰状细胞合作中心、波士顿血友病中心的分包站点以及 DFCI/哈佛大学癌症中心的资源。由每个关键领域的专家组成、代表所有六家机构/医院的咨询委员会将监督该项目并充当招生委员会。学者申请者将主要从成员医院的血液学/肿瘤学和输血医学培训项目中抽取。通常，学员将花费两年的时间作为学者，在进行教学培训的同时进行独立的研究项目。非恶性血液学系列研讨会将汇集来自波士顿血液学界的学者、他们的导师、项目教师和其他血液学家。对计划和学员进展的正式年度评估将用于持续的计划改进。